Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy

References

• Klastersky, J.; Zinner, S.H.; Calandra, T.; Gaya, H.; Glauser, M.P.; Meunier, F.; Rossi, M.; Schimpff, S.C.; Tattersall, M.; Viscoli, C. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: Lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988, 24 Suppl 1,S35,35–45.
   PubMedGoogle Scholar
• Kuderer, N.M.; Dale, D.C.; Crawford, J.; Cosler, L.E.; Lyman, G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006,106(10), 2258–66.
   PubMed Web of Science ®Google Scholar
• Santolaya, M.E.; Alvarez, A.M.; Avilés, C.L.; Becker, A.; Mosso, C.; O’Ryan, M.; Payá, E.; Salgado, C.; Silva, P.; Topelberg, S.; Tordecilla, J.; Varas, M.; Villarroel, M.; Viviani, T.; Zubieta, M. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007, 26(9), 794–8.
   PubMed Web of Science ®Google Scholar
• Watson, R.S.; Carcillo, J.A.; Linde-Zwirble, W.T.; Clermont, G.; Lidicker, J.; Angus, D.C. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003(5), 167, 695–701.
   PubMed Web of Science ®Google Scholar
• Mendes, A.V.; Sapolnik, R.; Mendonça, N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J). 2007, 83 (2 Suppl), S54–63.
   Web of Science ®Google Scholar
• Fisher, C.J. Jr; Yan, SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 2000, 28(9 Suppl), S49–56.
   Web of Science ®Google Scholar
• Esmon, C.T. The protein C pathway. Chest. 2000, 124(3 Suppl), 26S–32S.
   Google Scholar
• Shua, F.; Kobayashia, H.; Fukudomeb, K.; Tsuneyoshib, N.; Kimotob, M.; Teraoa, T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor dependent manner. FEBS Lett. 2000, 477(3), 208–212.
   PubMed Web of Science ®Google Scholar
• Yan, S.B.; Helterbrand, J.D.; Hartman, D.L.; Wright, T.J.; Bernard, G.R. Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001,120(3), 915–22.
   PubMed Web of Science ®Google Scholar
• Lorente, J.A.; García-Frade, L.J.; Landín, L.; de Pablo, R.; Torrado, C.; Renes, E.; García-Avello. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993,103(5), 1536–42.
   PubMed Web of Science ®Google Scholar
• Betrosian, A.P; Memos, N.; Theoddossiades, G.; Douzinas, E.E. Protein C concentrate in adult septic patients. Intens Care Med. 2008 Jul 16.
   Web of Science ®Google Scholar
• Ettingshausen, C.E; Veldmann, A.; Beeg, T.; Schneider, W.; Jäger, G.; Kreuz, W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost. 1999, 25(6), 537–41.
   PubMed Web of Science ®Google Scholar
• Smith, O.P.; White, B.; Vaughan, D.; Rafferty, M.; Claffey, L.; Lyons, B.; Casey, W. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997, 350(9091), 1590–3.
   PubMed Web of Science ®Google Scholar
• White, B.; Livingstone, W.; Murphy, C.; Hodgson, A.; Rafferty, M.; Smith, O.P. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000, 96(12), 3719–24.
   PubMed Web of Science ®Google Scholar
• de Kleijn E.D.; de Groot R.; Hack C.E.; Mulder P.G.; Engl W.; Moritz B.; Joosten K.F.; Hazelzet J.A. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med. 2003, 31(6), 1839–47.
   PubMed Web of Science ®Google Scholar
• Mammen, E.F. The hematological manifestations of sepsis. J Antimicrob Chemother. 1998,41 Suppl A, 17–24.
   PubMed Web of Science ®Google Scholar
• Kuhle, S.; Male, C.; Mitchell, L. Developmental hemostasis: Pro- and anticoagulant systems during childhood. Semin Thromb Hemost. 2003,29(4), 329–38.
   PubMed Web of Science ®Google Scholar
• Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; Fisher, C.J. Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344(10), 699–709.
   PubMed Web of Science ®Google Scholar
• Shorr, A.F; Bernard, G.R.; Dhainaut, J.F.; Russel, J.R.; Macias, L.W.; Nelson, D.R; Sundin, D.P. Protein C concentrations in severe sepsis: An early directional change in plasma levels predict outcome. Crit Care. 2006,10(3), R92.
   Web of Science ®Google Scholar
• Feffer, SE; Carmosino, LS; Fox, RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989,63(7), 1303–7.
   PubMed Web of Science ®Google Scholar
• Goodnough, L.T.; Saito, H.; Manni, A.; Jones, P.K.; Pearson, O.H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984,54(7), 1264–8.
   PubMed Web of Science ®Google Scholar
• Risseeuw-Appel, I.M.; Dekker, I.; Hop, W.C.; Hählen, K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized study. Med Pediatr Oncol. 1994,23(4), 335–43.
   PubMedGoogle Scholar
• Athale, U.H.; Chan, A.K. Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: Effects of host environment. Thromb Res. 2003,111(6), 321–7.
   PubMed Web of Science ®Google Scholar
• Rice, T.W. Treatment of severe sepsis: Where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vasc Health Risk Manag. 2006,2(1),3–18.
   PubMedGoogle Scholar
• Pettenazzo, A.; Malusa, T. Use of protein C concentrate in critical conditions: Clinical experience in pediatric patients with sepsis. Minerva Anestesiol. 2004,70(5), 357–63.
   PubMedGoogle Scholar
• Silvani, P.; Camporesi, A.; Licari, E.; Wolfler, A. Use of protein C concentrate in pediatric patients with sepsis. Minerva Anestesiol. 2005, 71(6), 373–8.
   PubMedGoogle Scholar